Feiyue Zheng, Yi Zhang, Shuang Chen, Xiang Weng, Yuefeng Rao, Hongmei Fang. Biomed Pharmacother 2020
Times Cited: 27
Times Cited: 27
Times Cited
Times Co-cited
Similarity
Antitumor efficacy of PARP inhibitors in homologous recombination deficient carcinomas.
Tianjin Yi, Yi Feng, Ravi Sundaram, Yan Tie, Heng Zheng, Yanping Qian, Di You, Tao Yi, Ping Wang, Xia Zhao. Int J Cancer 2019
Tianjin Yi, Yi Feng, Ravi Sundaram, Yan Tie, Heng Zheng, Yanping Qian, Di You, Tao Yi, Ping Wang, Xia Zhao. Int J Cancer 2019
13
An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer.
Monjri M Shah, Zachary C Dobbin, Somaira Nowsheen, Monica Wielgos, Ashwini A Katre, Ronald D Alvarez, Panagiotis A Konstantinopoulos, Eddy S Yang, Charles N Landen. Gynecol Oncol 2014
Monjri M Shah, Zachary C Dobbin, Somaira Nowsheen, Monica Wielgos, Ashwini A Katre, Ronald D Alvarez, Panagiotis A Konstantinopoulos, Eddy S Yang, Charles N Landen. Gynecol Oncol 2014
7
DYNLL1 binds to MRE11 to limit DNA end resection in BRCA1-deficient cells.
Yizhou Joseph He, Khyati Meghani, Marie-Christine Caron, Chunyu Yang, Daryl A Ronato, Jie Bian, Anchal Sharma, Jessica Moore, Joshi Niraj, Alexandre Detappe,[...]. Nature 2018
Yizhou Joseph He, Khyati Meghani, Marie-Christine Caron, Chunyu Yang, Daryl A Ronato, Jie Bian, Anchal Sharma, Jessica Moore, Joshi Niraj, Alexandre Detappe,[...]. Nature 2018
7
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs.
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
Sven Rottenberg, Janneke E Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O H Nygren, Serge A L Zander, Patrick W B Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau,[...]. Proc Natl Acad Sci U S A 2008
7
Biomarkers for Homologous Recombination Deficiency in Cancer.
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
Michal M Hoppe, Raghav Sundar, David S P Tan, Anand D Jeyasekharan. J Natl Cancer Inst 2018
7
Gene-panel sequencing and the prediction of breast-cancer risk.
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
Douglas F Easton, Paul D P Pharoah, Antonis C Antoniou, Marc Tischkowitz, Sean V Tavtigian, Katherine L Nathanson, Peter Devilee, Alfons Meindl, Fergus J Couch, Melissa Southey,[...]. N Engl J Med 2015
7
The clinical importance of assessing tumor hypoxia: relationship of tumor hypoxia to prognosis and therapeutic opportunities.
Joseph C Walsh, Artem Lebedev, Edward Aten, Kathleen Madsen, Liane Marciano, Hartmuth C Kolb. Antioxid Redox Signal 2014
Joseph C Walsh, Artem Lebedev, Edward Aten, Kathleen Madsen, Liane Marciano, Hartmuth C Kolb. Antioxid Redox Signal 2014
7
Targeting homologous recombination repair defects in cancer.
Bastiaan Evers, Thomas Helleday, Jos Jonkers. Trends Pharmacol Sci 2010
Bastiaan Evers, Thomas Helleday, Jos Jonkers. Trends Pharmacol Sci 2010
7
The Importance of Poly(ADP-Ribose) Polymerase as a Sensor of Unligated Okazaki Fragments during DNA Replication.
Hana Hanzlikova, Ilona Kalasova, Annie A Demin, Lewis E Pennicott, Zuzana Cihlarova, Keith W Caldecott. Mol Cell 2018
Hana Hanzlikova, Ilona Kalasova, Annie A Demin, Lewis E Pennicott, Zuzana Cihlarova, Keith W Caldecott. Mol Cell 2018
7
Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells.
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier,[...]. Nat Cell Biol 2018
Harveer Dev, Ting-Wei Will Chiang, Chloe Lescale, Inge de Krijger, Alistair G Martin, Domenic Pilger, Julia Coates, Matylda Sczaniecka-Clift, Wenming Wei, Matthias Ostermaier,[...]. Nat Cell Biol 2018
7
Exploring and comparing adverse events between PARP inhibitors.
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
Christopher J LaFargue, Graziela Z Dal Molin, Anil K Sood, Robert L Coleman. Lancet Oncol 2019
7
A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation.
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
Marta Castroviejo-Bermejo, Cristina Cruz, Alba Llop-Guevara, Sara Gutiérrez-Enríquez, Mandy Ducy, Yasir Hussein Ibrahim, Albert Gris-Oliver, Benedetta Pellegrino, Alejandra Bruna, Marta Guzmán,[...]. EMBO Mol Med 2018
7
Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Sarah S Bernards, Kathryn P Pennington, Maria I Harrell, Kathy J Agnew, Rochelle L Garcia, Barbara M Norquist, Elizabeth M Swisher. Gynecol Oncol 2018
Sarah S Bernards, Kathryn P Pennington, Maria I Harrell, Kathy J Agnew, Rochelle L Garcia, Barbara M Norquist, Elizabeth M Swisher. Gynecol Oncol 2018
7
Mechanisms of DNA damage, repair, and mutagenesis.
Nimrat Chatterjee, Graham C Walker. Environ Mol Mutagen 2017
Nimrat Chatterjee, Graham C Walker. Environ Mol Mutagen 2017
7
BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
Kara N Maxwell, Bradley Wubbenhorst, Brandon M Wenz, Daniel De Sloover, John Pluta, Lyndsey Emery, Amanda Barrett, Adam A Kraya, Ioannis N Anastopoulos, Shun Yu,[...]. Nat Commun 2017
7
Biomarkers of Response and Resistance to DNA Repair Targeted Therapies.
Elizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Elizabeth M Swisher. Clin Cancer Res 2016
Elizabeth H Stover, Panagiotis A Konstantinopoulos, Ursula A Matulonis, Elizabeth M Swisher. Clin Cancer Res 2016
7
RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
C Cruz, M Castroviejo-Bermejo, S Gutiérrez-Enríquez, A Llop-Guevara, Y H Ibrahim, A Gris-Oliver, S Bonache, B Morancho, A Bruna, O M Rueda,[...]. Ann Oncol 2018
7
Functional Ex Vivo Assay Reveals Homologous Recombination Deficiency in Breast Cancer Beyond BRCA Gene Defects.
Titia G Meijer, Nicole S Verkaik, Anieta M Sieuwerts, Job van Riet, Kishan A T Naipal, Carolien H M van Deurzen, Michael A den Bakker, Hein F B M Sleddens, Hendrikus-Jan Dubbink, T Dorine den Toom,[...]. Clin Cancer Res 2018
Titia G Meijer, Nicole S Verkaik, Anieta M Sieuwerts, Job van Riet, Kishan A T Naipal, Carolien H M van Deurzen, Michael A den Bakker, Hein F B M Sleddens, Hendrikus-Jan Dubbink, T Dorine den Toom,[...]. Clin Cancer Res 2018
7
A marker of homologous recombination predicts pathologic complete response to neoadjuvant chemotherapy in primary breast cancer.
Monika Graeser, Afshan McCarthy, Christopher J Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E Smith, Jorge S Reis-Filho,[...]. Clin Cancer Res 2010
Monika Graeser, Afshan McCarthy, Christopher J Lord, Kay Savage, Margaret Hills, Janine Salter, Nicholas Orr, Marina Parton, Ian E Smith, Jorge S Reis-Filho,[...]. Clin Cancer Res 2010
7
Landscape of somatic mutations in 560 breast cancer whole-genome sequences.
Serena Nik-Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, Xueqing Zou, Inigo Martincorena, Ludmil B Alexandrov, Sancha Martin, David C Wedge,[...]. Nature 2016
Serena Nik-Zainal, Helen Davies, Johan Staaf, Manasa Ramakrishna, Dominik Glodzik, Xueqing Zou, Inigo Martincorena, Ludmil B Alexandrov, Sancha Martin, David C Wedge,[...]. Nature 2016
7
Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers.
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
Wataru Sakai, Elizabeth M Swisher, Beth Y Karlan, Mukesh K Agarwal, Jake Higgins, Cynthia Friedman, Emily Villegas, Céline Jacquemont, Daniel J Farrugia, Fergus J Couch,[...]. Nature 2008
7
Why BRCA mutations are not tumour-agnostic biomarkers for PARP inhibitor therapy.
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha. Nat Rev Clin Oncol 2019
Nicola J Curtin, Yvette Drew, Sweta Sharma-Saha. Nat Rev Clin Oncol 2019
16
Identification of genes with differential expression in chemoresistant epithelial ovarian cancer using high-density oligonucleotide microarrays.
Woong Ju, Byong Chul Yoo, Il-Jin Kim, Jae Weon Kim, Seung Cheol Kim, Hyo Pyo Lee. Oncol Res 2009
Woong Ju, Byong Chul Yoo, Il-Jin Kim, Jae Weon Kim, Seung Cheol Kim, Hyo Pyo Lee. Oncol Res 2009
7
Molecular mechanisms of drug resistance in ovarian cancer.
Leyla Norouzi-Barough, Mohammad Reza Sarookhani, Mohammadreza Sharifi, Sahar Moghbelinejad, Saranaz Jangjoo, Rasoul Salehi. J Cell Physiol 2018
Leyla Norouzi-Barough, Mohammad Reza Sarookhani, Mohammadreza Sharifi, Sahar Moghbelinejad, Saranaz Jangjoo, Rasoul Salehi. J Cell Physiol 2018
7
Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes.
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
Darren R Hodgson, Brian A Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J O'Connor, Tony W Ho, Jane D Robertson, Jerry S Lanchbury,[...]. Br J Cancer 2018
7
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
Ilirjana Bajrami, Jessica R Frankum, Asha Konde, Rowan E Miller, Farah L Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper,[...]. Cancer Res 2014
Ilirjana Bajrami, Jessica R Frankum, Asha Konde, Rowan E Miller, Farah L Rehman, Rachel Brough, James Campbell, David Sims, Rumana Rafiq, Sean Hooper,[...]. Cancer Res 2014
7
Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy.
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
Yong Fang, Daniel J McGrail, Chaoyang Sun, Marilyne Labrie, Xiaohua Chen, Dong Zhang, Zhenlin Ju, Christopher P Vellano, Yiling Lu, Yongsheng Li,[...]. Cancer Cell 2019
7
Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
Qian Zhong, Hong-Ling Peng, Xia Zhao, Lin Zhang, Wei-Ting Hwang. Clin Cancer Res 2015
7
Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate.
Cecilia E Ström, Fredrik Johansson, Mathias Uhlén, Cristina Al-Khalili Szigyarto, Klaus Erixon, Thomas Helleday. Nucleic Acids Res 2011
Cecilia E Ström, Fredrik Johansson, Mathias Uhlén, Cristina Al-Khalili Szigyarto, Klaus Erixon, Thomas Helleday. Nucleic Acids Res 2011
7
Loss of E2F7 confers resistance to poly-ADP-ribose polymerase (PARP) inhibitors in BRCA2-deficient cells.
Kristen E Clements, Tanay Thakar, Claudia M Nicolae, Xinwen Liang, Hong-Gang Wang, George-Lucian Moldovan. Nucleic Acids Res 2018
Kristen E Clements, Tanay Thakar, Claudia M Nicolae, Xinwen Liang, Hong-Gang Wang, George-Lucian Moldovan. Nucleic Acids Res 2018
7
Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
7
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
Mansoor R Mirza, Bradley J Monk, Jørn Herrstedt, Amit M Oza, Sven Mahner, Andrés Redondo, Michel Fabbro, Jonathan A Ledermann, Domenica Lorusso, Ignace Vergote,[...]. N Engl J Med 2016
7
Poly(ADP-ribose): novel functions for an old molecule.
Valérie Schreiber, Françoise Dantzer, Jean-Christophe Ame, Gilbert de Murcia. Nat Rev Mol Cell Biol 2006
Valérie Schreiber, Françoise Dantzer, Jean-Christophe Ame, Gilbert de Murcia. Nat Rev Mol Cell Biol 2006
7
A comparative pharmacokinetic study of PARP inhibitors demonstrates favorable properties for niraparib efficacy in preclinical tumor models.
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
Kaiming Sun, Keith Mikule, Zebin Wang, Grace Poon, Aparajitha Vaidyanathan, Gillian Smith, Zhi-Yi Zhang, Jeffrey Hanke, Sridhar Ramaswamy, Jing Wang. Oncotarget 2018
7
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial.
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
Eric Pujade-Lauraine, Jonathan A Ledermann, Frédéric Selle, Val Gebski, Richard T Penson, Amit M Oza, Jacob Korach, Tomasz Huzarski, Andrés Poveda, Sandro Pignata,[...]. Lancet Oncol 2017
7
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Michael Friedlander, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul Harnett, Michael Millward, Joanne Lundy, Alison Freimund, Christie Norris, Song Mu,[...]. Lancet Oncol 2019
Michael Friedlander, Tarek Meniawy, Ben Markman, Linda Mileshkin, Paul Harnett, Michael Millward, Joanne Lundy, Alison Freimund, Christie Norris, Song Mu,[...]. Lancet Oncol 2019
7
Activation of STING-Dependent Innate Immune Signaling By S-Phase-Specific DNA Damage in Breast Cancer.
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
Eileen E Parkes, Steven M Walker, Laura E Taggart, Nuala McCabe, Laura A Knight, Richard Wilkinson, Karen D McCloskey, Niamh E Buckley, Kienan I Savage, Manuel Salto-Tellez,[...]. J Natl Cancer Inst 2016
7
Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
Melinda L Telli, Kirsten M Timms, Julia Reid, Bryan Hennessy, Gordon B Mills, Kristin C Jensen, Zoltan Szallasi, William T Barry, Eric P Winer, Nadine M Tung,[...]. Clin Cancer Res 2016
7
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
Nicolai J Birkbak, Zhigang C Wang, Ji-Young Kim, Aron C Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J Dirk Iglehart,[...]. Cancer Discov 2012
7
PARPi Triggers the STING-Dependent Immune Response and Enhances the Therapeutic Efficacy of Immune Checkpoint Blockade Independent of BRCAness.
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
Jianfeng Shen, Wei Zhao, Zhenlin Ju, Lulu Wang, Yang Peng, Marilyne Labrie, Timothy A Yap, Gordon B Mills, Guang Peng. Cancer Res 2019
7
Olaparib for Metastatic Castration-Resistant Prostate Cancer.
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
Johann de Bono, Joaquin Mateo, Karim Fizazi, Fred Saad, Neal Shore, Shahneen Sandhu, Kim N Chi, Oliver Sartor, Neeraj Agarwal, David Olmos,[...]. N Engl J Med 2020
7
PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer.
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
Constantia Pantelidou, Olmo Sonzogni, Mateus De Oliveria Taveira, Anita K Mehta, Aditi Kothari, Dan Wang, Tanvi Visal, Michelle K Li, Jocelin Pinto, Jessica A Castrillon,[...]. Cancer Discov 2019
7
BRCA1-BARD1 promotes RAD51-mediated homologous DNA pairing.
Weixing Zhao, Justin B Steinfeld, Fengshan Liang, Xiaoyong Chen, David G Maranon, Chu Jian Ma, Youngho Kwon, Timsi Rao, Weibin Wang, Chen Sheng,[...]. Nature 2017
Weixing Zhao, Justin B Steinfeld, Fengshan Liang, Xiaoyong Chen, David G Maranon, Chu Jian Ma, Youngho Kwon, Timsi Rao, Weibin Wang, Chen Sheng,[...]. Nature 2017
7
Restored replication fork stabilization, a mechanism of PARP inhibitor resistance, can be overcome by cell cycle checkpoint inhibition.
Brittany Haynes, Junko Murai, Jung-Min Lee. Cancer Treat Rev 2018
Brittany Haynes, Junko Murai, Jung-Min Lee. Cancer Treat Rev 2018
7
Synthetic lethality between BRCA1 deficiency and poly(ADP-ribose) polymerase inhibition is modulated by processing of endogenous oxidative DNA damage.
Sara Giovannini, Marie-Christine Weller, Simone Repmann, Holger Moch, Josef Jiricny. Nucleic Acids Res 2019
Sara Giovannini, Marie-Christine Weller, Simone Repmann, Holger Moch, Josef Jiricny. Nucleic Acids Res 2019
14
Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma.
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I Harrell, Giada V Zapparoli, Alison Hadley, Robert Holian, Emma Boehm,[...]. Nat Commun 2018
Olga Kondrashova, Monique Topp, Ksenija Nesic, Elizabeth Lieschke, Gwo-Yaw Ho, Maria I Harrell, Giada V Zapparoli, Alison Hadley, Robert Holian, Emma Boehm,[...]. Nat Commun 2018
7
The role of poly(ADP-ribose) polymerase inhibitors in the treatment of cancer and methods to overcome resistance: a review.
Mausam Patel, Somaira Nowsheen, Sanjay Maraboyina, Fen Xia. Cell Biosci 2020
Mausam Patel, Somaira Nowsheen, Sanjay Maraboyina, Fen Xia. Cell Biosci 2020
7
Tumour lineage shapes BRCA-mediated phenotypes.
Philip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, Preethi Srinivasan, Shweta S Chavan, Noah D Friedman, Ezra Y Rosen, Allison L Richards, Nancy Bouvier, S Duygu Selcuklu,[...]. Nature 2019
Philip Jonsson, Chaitanya Bandlamudi, Michael L Cheng, Preethi Srinivasan, Shweta S Chavan, Noah D Friedman, Ezra Y Rosen, Allison L Richards, Nancy Bouvier, S Duygu Selcuklu,[...]. Nature 2019
7
Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.